ArticleInternational journal of women's health2024
The Effect of Traditional Chinese Medicine Treatment on the Cumulative Live Birth Rate of Patients with Poor Ovarian Response to the Patient-Oriented Strategies Encompassing Individualized Oocyte Number Criteria.
Article in International journal of women's health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study analyzed the role of traditional Chinese medicine (TCM) treatment on the cumulative live birth rate (CLBR) in women with poor ovarian response to the patient-oriented strategies encompassing individualized oocyte number (POSEIDON) criteria. Methods: This cohort study selected 3347 patients with low ovarian response and divided them into four subgroups according to the POSEIDON criteria: Group 1 (n=947), Group 2 (n=778), Group 3 (n=164), and Group 4 (n=1458). Logistic regression analysis was used to evaluate the role of TCM treatment on the CLBR of patients with poor ovarian response to POSEIDON criteria. Results: In the unadjusted model, TCM treatment might be related to the heightened CLBR (OR=2.052, 95% CI: 1.745-2.413). After adjusting for the POSEIDON group, a higher CLBR was identified in those with TCM treatment (OR=1.927, 95% CI: 1.615-2.300). In Model 3, covariates including the POSEIDON group, age, body mass index (BMI), anti-mullerian hormone (AMH), and/or antral follicle count (AFC) were adjusted, and TCM treatment was associated with elevated CLBR of patients with poor ovarian response to the POSEIDON criteria (OR=1.905, 95% CI: 1.586-2.289). This suggested that TCM increased CLBR by 19.05% in patients who used TCM compared with those who did not. Subgroup analysis indicated that TCM treatment might increase the CLBR of patients in POSEIDON criteria Group 1 (OR=1.83, 95% CI: 1.33-2.51), indicating that TCM elevated the CLBR by 8.3% in POSEIDON criteria Group 1. Conclusion: TCM treatment was related to increased CLBR in patients with poor ovarian response to the POSEIDON criteria.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.